手术切除加药盒导管植入治疗肝转移瘤的临床研究

目的　研究肝转移瘤手术切除加肝动脉药盒导管植入系统灌注栓塞的临床疗效。方法　将 46例肝转移瘤患者随机分为A、B两组 ,A组手术切除加药盒导管植入系统 (PCS)综合治疗 ,B组单纯转移瘤手术切除。结果　A组 1、3年肝内复发分别为 3例和 10例 ;B组为 9例和 17例 ;A组 1、3年生存分别为 2 0例和 15例 ;B组为 15例和 8例 ;两组 3年生存率比较差异均有显著性 (χ2 =4.2 61,P <0 .0 5 ) ;A组平均生存期为 3 4.7月 ,B组平均生存期为 2 0 .1个月 ,两组生存期比较差异有显著性 (t =6.5 ,P <0 .0 5 )。结论　手术切除加肝动脉药盒导管植入系统灌注化疗栓塞治疗方案是肝转移瘤治疗比较有效的手段之一。

The hepatectomy combined with percutaneous PCS implantation in treatment of hepatatic metastatic neoplasms

Objective To study the clinical efficacy of hepatectomy combined with percutaneous port-catheter system (PCS) implantation in the treatment of hepatatic metastatic neoplasms. Methods 46 patients with hepatatic metastatic neoplasms were allocated to groups A and B. Group A received the treatmnet of hepatectomy combined with percutaneous PCS implantation, and group B were given single hepatectomy. Results The 1～, 3～year hepatatic recurrent rates were found in 3 and 10 cases in group A, respectively; and 9 and 17 cases in group B, respectively. In group A, the 1～, 3～year survival rates were found in 20 and 15 cases, respectively; and in group B, there were 15 and 8 cases, respectively. There was statistically significant difference in the 3-year survival rate between group A and group B (χ2=4.261, P<0.05). The mean survival period were 34.7 months in group A, and 20.1 months in group B, there were statistical difference between these two groups (t=6.5, P<0.05). Conclusion The hepatectomy combined with percutaneous PCS implantation therapy is effective in the treatment of hepatatic metastatic neoplasms.